|
|
|
|
|
||||||||||||
|
|
|
|
|
|
|
|
價值評估 |
盈利(現時/預測)
-12.12/-3.24
|
企業價值
7.79M
|
資產負債 |
每股賬面淨值
-12.98
|
現金流量 |
現金流量率
--
|
損益表 |
收益
3.02M
|
每股收益
0.37
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|

同行比較之報價最少15分鐘延遲
業務概覽
|
|||
NAYA Biosciences Inc is a life science portfolio company dedicated to bringing breakthrough treatments to patients in oncology, autoimmune diseases, and women's health. Its portfolio of assets currently includes NY-303, a GPC3 x NKp46 bifunctional antibody for the treatment of hepatocellular carcinoma (HCC) with a mode of action targeting non-responders to the current immunotherapy standard of care. |